About Us

Lorem ipsum dolor sit amet, et ipsum electram definitiones

Corporate Overview

Founded in March 2014, Trifecta MedTek has dedicated over a decade to excellence in analytical testing and pre-clinical R&D. With rigorous science at our core, we have established an integrated platform encompassing pharmaceutical analysis, pharmacology research, toxicology assessment, and antibody process development.

As a strategic R&D partner, Trifecta MedTek provides comprehensive CRO services across diverse modalities, including small molecules, antibodies, exosomes, and cell therapy products, with the technical capacity to support clinical bioanalysis. By leveraging our multidisciplinary technical team, state-of-the-art instrumentation, robust quality management systems, and strict regulatory compliance (GLP, ISO/IEC 17025), we empower clients to maintain precise control over research data and quality throughout the critical transition from early development to clinical translation—accelerating the “Bench-to-Market” commercialization process.

Corporate Overview

Founded in March 2014, Trifecta MedTek has dedicated over a decade to excellence in analytical testing and pre-clinical R&D. With rigorous science at our core, we have established an integrated platform encompassing pharmaceutical analysis, pharmacology research, toxicology assessment, and antibody process development.

As a strategic R&D partner, Trifecta MedTek provides comprehensive CRO services across diverse modalities, including small molecules, antibodies, exosomes, and cell therapy products, with the technical capacity to support clinical bioanalysis. By leveraging our multidisciplinary technical team, state-of-the-art instrumentation, robust quality management systems, and strict regulatory compliance (GLP, ISO/IEC 17025), we empower clients to maintain precise control over research data and quality throughout the critical transition from early development to clinical translation—accelerating the “Bench-to-Market” commercialization process.

Corporate Milestones

Lorem ipsum dolor sit amet, et ipsum electram definitiones

  • 2026

    Strategically merged into Bestat Group. This integration enables a full-service portfolio bridging preclinical R&D to clinical development.

  • Cumulative service to over 60 biotech companies, research institutes, and legal entities.

    2025

  • 2021

    Completed Taiwan’s first comprehensive preclinical safety and stability assessment for a gene therapy product.

  • Completed the first allogeneic cell therapy GLP toxicology and biodistribution study.

    2020

  • 2016

    Successfully completed OECD GLP compliance registration.

  • Achieved ISO/IEC 17025 laboratory accreditation.

    2014

  • 2013

    Official incorporation.

Quality & Certifications

Trifecta MedTek is committed to premium contract research services adhering to international regulatory standards. We have established a robust quality management system to deliver precise analytical testing for food, pharmaceuticals, and biological samples (including clinical specimens), alongside high-quality non-clinical CRO services. We ensure every data point possesses rigorous regulatory traceability, assisting our partners in generating globally recognized reports to advance their international R&D and clinical milestones.

Laboratory Accreditations